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In this issue ofCell StemCell, Di Giorgio et al. (2008) andMarchetto et al. (2008) culturemotor neurons derived
from human embryonic stem cells with astrocytes expressing mutant SOD1. In these human ALS models,
motor neurons are selectively destroyed bymutant astrocyte-secreted factors, and potential neuroprotective
pathways are revealed.Amyotrophic Lateral Sclerosis (ALS) is
a fatal disease, characterized by the de-
generation of somatic motor neurons in
the spinal cord, brain stem, and cortex.
ALS is dominantly inherited in approxi-
mately 10% of patients (familial ALS,
fALS), but in 90% of patients, there is no
apparent genetic linkage (sporadic ALS).
Approximately 20% of fALS cases have
been linked to mutations in the gene en-
coding Cu/Zn superoxide dismutase 1
(SOD1). SOD1 converts naturally occur-
ring but harmful superoxide radicals to
molecular oxygen and hydrogen perox-
ide. Mutant SOD1 animal models have
provided abundant information regarding
the possible mechanisms of disease.
Overexpression of mutant forms of hu-
man SOD1 in rodents results in ALS-like
motor neuron disease, indicating that
a toxic gain of function rather than a loss
of enzymatic activity is the likely cause
of fALS. Further analyses of such trans-
genic animals suggest that disease initia-
tion is caused by direct damage of motor
neurons (cell autonomous) while progres-
sion is dependent on nonneuronal cells,
such as astrocytes and microglia (non-
cell autonomous) (Boillee et al., 2006).
Several drug therapies have exhibited
benefical effects in SOD1 transgenic
models; however, the same candidates
have not been successful in human clini-
cal trials, indicating that current ALS ro-
dent models provide only a limited insight
into the pathogenesis of human ALS.
Thus, developing humanized ALS modelsis a critical step toward identifying suc-
cessful therapeutic alternatives.
In this issue of Cell Stem Cell, two
groups, Di Giorgio et al. (2008) and Mar-
chetto et al. (2008), show that human em-
bryonic stem cell-derived motor neurons
are sensitive to toxic effects of mutant
SOD1 overexpressing glia, whereas ex-
posure to wild-type SOD1 glia left motor
neurons unharmed. In both studies, the
Hb9 promoter was used to specifically
label motor neurons by eGFP expression.
While Di Giorgio and colleagues made
a stable Hb9-eGFP hESC line, Marchetto
et al. utilized a lenti-Hb9-eGFP construct
to label motor neurons in differentiated
hESC cultures. About 50 percent of
human motor neurons were lost when co-
cultured either with primary human astro-
cytes infected with a lenti mutant SOD1
construct for 4 weeks (Marchetto et al.,
2008) or mutant SOD1-overexpressing
rodent astrocytes or their conditioned
media for 10–20 days (Di Giorgio et al.,
2008). Factors responsible for the toxicity
of ALS model glia included prostaglan-
dins (Di Giorgio et al., 2008) and proin-
flammatory cytokines (Marchetto et al.,
2008).
Overexpression of different SOD1 point
mutations in glia induced similar levels of
motor neuron loss in both studies. The de-
generative effect appeared specific to glia
since mutant SOD1 overexpressing fibro-
blasts were not harmful to motor neurons,
confirming previous findings utilizing
mouse motor neurons (Di Giorgio et al.,Cell Stem Cell 32007; Nagai et al., 2007). Both studies
also show that interneurons remained un-
affected, suggesting that the toxic effects
elicited by astrocytes are relatively target
cell-specific. The observed selective tox-
icity raises some interesting questions
for future investigation. Specifically, while
motor neuron death is the prominent
feature in ALS, spinal interneurons also
degenerate during disease progression.
In fact, some evidence suggests that
a majority of ventro-lateral and medio-
lateral spinal interneurons degenerate in
mutant SOD1 mouse models prior to on-
set of motor neuron loss (Martin et al.,
2007) and activation of glia (Tu et al.,
1996). Thus, if mutant SOD1-activated as-
trocytes are not responsible for the early
degeneration of these interneurons, what
other cell types participate in their demise
and are cell autonomous or non-cell
autonomous events required?
Consistent with previous studies on
mouse ALS model systems (Nagai
et al., 2007; Pehar et al., 2004), both Di
Giorgio et al. and Marchetto et al. found
that the toxicity of mutant SOD1 overex-
pressing glia was mediated by factors
released into the cell culture media. In an
effort to isolate the soluble mediators re-
sponsible, Di Giorgio and colleagues
used microarrays to identify genes that
were uniquely transcribed in astrocytes
overexpressing mutant SOD1. One of
the results from the screen, prostaglandin
D2 (PGD2), could by itself cause motor
neuron loss at levels similar to that, December 4, 2008 ª2008 Elsevier Inc. 575
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pressing astrocytes. Interestingly, block-
ing the PDG2 receptor significantly res-
cued motor neurons plated on mutant
SOD1 overexpressing astrocytes. How-
ever, the rescue was modest, indicating
that mutant astrocyte-induced degenera-
tion of motor neurons is mediated only in
part by secreted PGD2. Inhibition of cy-
clooxygenase 2 (Cox-2), the enzyme in-
volved in prostaglandin synthesis, has
been shown to delay onset of disease in
ALS mouse models. However, as dis-
cussed above, a clinical trial failed to
show benefit for patients with manifest
ALS, so therefore, blocking prostaglan-
dins alone is likely not sufficient for signif-
icant clinical benefits, at least in cases in
which disease progression has been
initiated. Marchetto and colleagues ob-
served that the cultured astrocytes acti-
vated an inflammatory response when ex-
pressing mutant SOD1, concomitant with
increased production of reactive oxygen
species (ROS) and proinflammatory cyto-
kines such as nitric oxide enzyme (iNOS),
chromogranin A, Cystatin C, and Nox2.
Blocking ROS production using the
Nox2 inhibitor apocynin rescued human
motor neurons from mutant SOD1-toxic-
ity, confirming recent data generated
from mutant mouse model experiments
(Harraz et al., 2008). Nox2 has also been
shown to be upregulated in the spinal
cord of sporadic ALS patients, indicating
that Nox2 could be a general therapeutic
drug target for ALS patients.
Several compounds tested in mutant
SOD1 animal models have succeeded in
delaying onset of disease, but very few
molecules, including IGF-I and VEGF,
have increased life span of the animals
when delivered after onset of symptoms.
Substances that delay or prevent disease576 Cell Stem Cell 3, December 4, 2008 ª20onset could, thus, potentially be of clinical
benefit provided that preclinical ALS bio-
markers can be identified. However, given
the current lack of such presymptomatic
markers, substances that can increase
the life-span of already affected individ-
uals represent a higher priority for clinical
development. Culture-based systems of
human stem cells and their derivatives,
such as those developed by Di Giorgio
et al. and Marchetto et al., could facilitate
the discovery of such neuroprotective
compounds with potential clinical rele-
vance. Notably, overexpression of mutant
SOD1 activates multiple detrimental bio-
chemical pathways, such as the NADPH
oxidase (Nox) cascade and its resulting
downstream overproduction of superox-
ide (Harraz et al., 2008). Mutants also
exhibit reduced degradation of misfolded
proteins, which may result in ER stress
and concomitant activation of ASK1 and
apoptosis (Nishitoh et al., 2008). Com-
bined, these results underscore that
many toxic pathways may need to be tar-
geted in concert to effectively protect the
functionality of motor neurons. Further-
more, it is not known whether glial cells
in patients elicit the same toxicity as the
ALS model astrocytes, as the latter com-
monly harbor multiple copies of mutant
SOD1. An analysis of induced pluripotent
stem cell (iPSC)-derived glial cells from
patients with mutant SOD1-induced ALS
(Dimos et al., 2008) could possibly reveal
whether a single gene copy renders hu-
man glial cells as toxic as those harboring
multiple mutant SOD1 copies. Derivation
of glial cells from patients with sporadic
ALS could reveal if the toxicity induced
by this population is consistent across dif-
ferent forms of ALS or dependent on the
particular cause(s) of the disease. Finally,
the ESC-based systems described in08 Elsevier Inc.these two studies could be used to inves-
tigate the cell autonomous events in
motor neurons that appear to initiate their
degeneration and that render mutant
SOD1-containing motor neurons more
vulnerable to the toxic effects of mutant
SOD1 glia than wild-type motor neurons
(Di Giorgio et al., 2007).
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